Multimodality Imaging to Predict Response to Systemic Treatment in XXXX with Advanced @entity14 .

@entity1 @entity419 @entity14 @entity1349
AIM: Aim of this study was to investigate the potential of @entity419 PET, diffusion weighted imaging (DWI) and susceptibility-weighted (T2*) MRI to predict response to systemic treatment in @entity1 with @entity14 . The predictive values of pretreatment measurements and of early changes one week after start of therapy, were evaluated. METHODS: Imaging was performed prior to and one week after start of first line chemotherapy in 39 @entity1 with @entity14 . @entity419 PET scans were performed on a PET/CT scanner and DWI and T2* were performed on a 1.5T MR scanner. The maximum standardized uptake values (SUV), total lesion glycolysis (TLG), apparent diffusion coefficient (ADC) and T2* value were assessed in the same lesions. Up to 5 liver metastases per @entity1 were analyzed. Outcome measures were progression free survival (PFS), @entity1349 ( @entity1349 ) and size response. RESULTS: Pretreatment, high SUVmax, high TLG, low ADC and high T2* were associated with a shorter @entity1349 . Low pretreatment ADC value was associated with shorter PFS. After 1 week a significant drop in SUVmax and rise in ADC were observed. The drop in SUV was correlated with the rise in ADC (r=-0.58, p=0.002). Neither change in ADC nor in SUV was predictive of PFS or @entity1349 . T2* did not significantly change after start of treatment. CONCLUSION: Pretreatment SUVmax, TLG, ADC, and T2* values in @entity14 are predictive of @entity1 outcome. Despite sensitivity of DWI and @entity419 PET for early treatment effects, change in these parameters was not predictive of long term outcome.
